Yes this will be the fundamental starting point for PAR and the FDA
Humira records ongoing SAE with their dosage schedule. FDA will not want to see this for Zilosul given the OA population size
- Forums
- ASX - By Stock
- Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
Yes this will be the fundamental starting point for PAR and the...
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.0¢ |
Change
-0.010(3.23%) |
Mkt cap ! $104.9M |
Open | High | Low | Value | Volume |
31.0¢ | 31.5¢ | 29.0¢ | $161.3K | 527.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 10756 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 62010 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 10756 | 0.300 |
1 | 99965 | 0.295 |
5 | 87991 | 0.290 |
3 | 38593 | 0.285 |
3 | 110000 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 50010 | 2 |
0.320 | 45000 | 2 |
0.325 | 50366 | 4 |
0.330 | 125773 | 4 |
0.335 | 10000 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online